Sinnamon Kim T, Courtney Aisling E, Maxwell A Peter, McNamee Peter T, Savage Geraldine, Fogarty Damian G
Regional Nephrology Unit, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, Northern Ireland, UK.
Nephrol Dial Transplant. 2007 Jul;22(7):1969-73. doi: 10.1093/ndt/gfm100. Epub 2007 Mar 12.
Post-renal transplant anaemia is a potentially reversible cardiovascular risk factor. Graft function, immunosuppressive agents and inhibition of the renin-angiotensin system have been implicated in its aetiology. The evaluation of erythropoietin (EPO) levels may contribute to understanding the relative contributions of these factors.
Two-hundred and seven renal transplant recipients attending the Belfast City Hospital were studied. Clinical and laboratory data were extracted from the medical records and laboratory systems.
Of the 207 patients (126 male), 47 (22.7%) were found to be anaemic (males, haemoglobin (Hb)<12 g/dl, females Hb<11 g/dl). The anaemic group had a significantly higher mean serum creatinine level (162.8 micromol/l vs 131.0 micromol/l, P<0.001) and lower mean estimated glomerular filtration rate (eGFR) (41.5 ml/min vs 54.9 ml/min, P<0.001) than the non-anaemic group. Individual immunosuppressive regimens were comparable between those with and those without anaemia. Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) administration was not more prevalent in those with anaemia compared with those without (36.2 vs 38.8%, P=0.88). There was a significant inverse correlation between Hb levels and serum EPO levels (R=-0.29, P<0.001), but not between EPO levels and eGFR (R=0.02, P=0.74). Higher EPO levels were predictive of anaemia, independent of eGFR in multivariate analysis.
Anaemia is common in post-renal transplant patients. The levels of renal function and serum EPO and not immunosuppressive regimens or ACE-I/ARB use, are strong and independent predictors of anaemia.
肾移植后贫血是一种潜在可逆的心血管危险因素。移植肾功能、免疫抑制剂以及肾素 - 血管紧张素系统的抑制作用均与该病病因相关。评估促红细胞生成素(EPO)水平可能有助于理解这些因素的相对作用。
对就诊于贝尔法斯特市医院的207例肾移植受者进行研究。从病历和实验室系统中提取临床和实验室数据。
在这207例患者(126例男性)中,47例(22.7%)被发现贫血(男性血红蛋白(Hb)<12 g/dl,女性Hb<11 g/dl)。贫血组的平均血清肌酐水平显著高于非贫血组(162.8 μmol/l对131.0 μmol/l,P<0.001),平均估计肾小球滤过率(eGFR)则显著低于非贫血组(41.5 ml/min对54.9 ml/min,P<0.001)。贫血患者与非贫血患者的个体免疫抑制方案具有可比性。与未使用贫血患者相比,使用血管紧张素转换酶抑制剂(ACE-I)或血管紧张素受体阻滞剂(ARB)的贫血患者并不更常见(36.2%对38.8%,P = 0.88)。Hb水平与血清EPO水平之间存在显著负相关(R = -0.29,P<0.001),但EPO水平与eGFR之间无相关性(R = 0.02,P = 0.74)。在多变量分析中,较高的EPO水平可独立于eGFR预测贫血。
贫血在肾移植后患者中很常见。肾功能和血清EPO水平而非免疫抑制方案或ACE-I/ARB的使用,是贫血的强有力且独立的预测因素。